BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25176223)

  • 1. Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study.
    Lorusso V; Giotta F; Bordonaro R; Maiello E; Del Prete S; Gebbia V; Filippelli G; Pisconti S; Cinieri S; Romito S; Riccardi F; Forcignanò R; Ciccarese M; Petrucelli L; Saracino V; Lupo LI; Gambino A; Leo S; Colucci G;
    Int J Oncol; 2014 Nov; 45(5):2137-42. PubMed ID: 25176223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
    Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
    J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
    Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
    Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
    Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
    Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
    J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
    Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
    J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.
    Livi L; Meattini I; Scotti V; De Luca Cardillo C; Galardi A; Iermano C; Sanchez L; Nori J; Mangoni M; Franzese C; Orzalesi L; Bertocci S; Agresti B; Masoni T; Bianchi S; Cataliotti L; Biti G
    J Chemother; 2011 Jun; 23(3):158-62. PubMed ID: 21742585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
    Norris B; Pritchard KI; James K; Myles J; Bennett K; Marlin S; Skillings J; Findlay B; Vandenberg T; Goss P; Latreille J; Rudinskas L; Lofters W; Trudeau M; Osoba D; Rodgers A
    J Clin Oncol; 2000 Jun; 18(12):2385-94. PubMed ID: 10856098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
    Vici P; Colucci G; Giotta F; Sergi D; Filippelli G; Perri P; Botti C; Vizza E; Carpino A; Pizzuti L; Latorre A; Giannarelli D; Lopez M; Di Lauro L
    J Exp Clin Cancer Res; 2011 Apr; 30(1):39. PubMed ID: 21481280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
    Overmoyer B; Silverman P; Holder LW; Tripathy D; Henderson IC
    Clin Breast Cancer; 2005 Jun; 6(2):150-7. PubMed ID: 16001993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
    Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
    Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
    Chow LW; Yip AY; Lang BH
    Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
    Chang AE; Wu QV; Jenkins IC; Specht JM; Gadi VK; Gralow JR; Salazar LG; Kurland BF; Linden HM
    Clin Breast Cancer; 2018 Feb; 18(1):e143-e149. PubMed ID: 29174203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.